Investing.com -- 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) stock dropped 16.9% in premarket trading Monday following the announcement of a partnership with GoodRx (NASDAQ:GDRX) to offer prescription savings on its malaria prevention drug ARAKODA.
The pharmaceutical company, which focuses on developing medicines for vector-borne diseases, revealed that the collaboration will provide eligible consumers with savings of up to 30% on ARAKODA (tafenoquine), the only FDA-approved, once-weekly prescription malaria prevention medication currently available in the U.S. market.
Starting February 2, 2026, patients will be able to access discounted pricing for ARAKODA at more than 70,000 pharmacies nationwide through GoodRx’s platform, or have the medication delivered to their homes when available.
ARAKODA is primarily prescribed for travelers heading to regions where malaria is endemic. The drug was discovered by Walter Reed Army Institute of Research and received FDA approval in 2018. It features a long terminal half-life of approximately 16 days, which allows for less-frequent dosing compared to other malaria prevention options.
The standard regimen for ARAKODA includes a loading phase of two 100mg tablets daily for three days before travel, followed by two 100mg tablets weekly during travel for up to six months, and two 100mg tablets in the week following travel.
Despite the potential benefits of increased accessibility through the GoodRx partnership, investors appeared to respond negatively to the news, sending shares lower in early trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.































